

Figure 4. Previous trials of serogroup B meningococcal vaccines have shown a relationship between the proportion of vaccinees who had a $\geq 4X$ rise in serum bactericidal antibody titre following vaccination (horizontal axis) and the protective efficacy of the vaccine (vertical axis). The points shown are for: the Norwegian vaccine given to children aged 14–16yrs (1); the Cuban vaccine given to children in Sao Paulo, Brazil, aged <2yrs (2), 2–4yrs (3), 4–7yrs (4); the Cuban vaccine given to children in Rio de Janeiro, Brazil, aged <2yrs (5), 2–4yrs (6), 4–9yrs (7); and an American vaccine given to children in Iquique, Chile, aged 1–4yrs (8) and 5–21yrs (9).^{10–15}

